NEW YORK (GenomeWeb News) – Rosetta Genomics and its research collaborators have published in the Journal of Clinical Oncology data from a study showing that the same biomarker used in the firm's miRNA-based test for squamous lung cancer provided 96 percent sensitivity.

The study, which was posted online Monday on the journal's website, included 262 patients and was conducted by Rehovot, Israel-based Rosetta and researchers from Columbia University, NYU Cancer Institute, and Sheba Medical Center.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: phylogenetic study of hepatitis E viruses in Swedish moose, recombination sites in the honeybee genome, and more.

Differences in DNA methylation could be used to distinguish between DNA samples obtained from identical twins, researchers say.

A retrovirus that's been integrated into the human genome appears to have a role in embryonic development, researchers report.

A report from MIT identifies areas of scientific research where declining research support is hindering needed advances.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.